Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

3.8%

1 terminated/withdrawn out of 26 trials

Success Rate

96.0%

+9.5% vs industry average

Late-Stage Pipeline

15%

4 trials in Phase 3/4

Results Transparency

58%

14 of 24 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 1

13(52.0%)

Phase 2

8(32.0%)

Phase 4

2(8.0%)

Phase 3

2(8.0%)

25Total

Phase 1(13)

Phase 2(8)

Phase 4(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT05979415Phase 2Terminated

Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Role: lead

NCT03513549Suspended

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Role: lead

NCT04645953Phase 2Completed

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

Role: lead

NCT04157933Phase 1Completed

Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease

Role: lead

NCT04327765Phase 1Completed

Staccato® Granisetron Multiple Dose PK

Role: lead

NCT03822364Phase 1Completed

Staccato Apomorphine Single and Multi Dose PK

Role: lead

NCT00789360Phase 1Completed

Staccato Loxapine Pulmonary Safety in Healthy Volunteers

Role: lead

NCT00543062Phase 1Completed

Staccato Prochlorperazine Thorough QT/QTc

Role: lead

NCT00444028Phase 1Completed

Staccato Loxapine Single Dose PK

Role: lead

NCT00610428Phase 2Completed

Staccato Prochlorperazine in Migraine (in Clinic)

Role: lead

NCT00422812Phase 2Completed

Staccato Prochlorperazine in Migraine (Out Patient)

Role: lead

NCT00369577Phase 2Completed

Staccato Loxapine in Agitation (Proof of Concept)

Role: lead

NCT01877642Phase 4Completed

ADASUVE-Lorazepam Drug-Drug Interaction

Role: lead

NCT01854710Phase 4Completed

ADASUVE 2-dose Thorough QT/QTc Study

Role: lead

NCT00628589Phase 3Completed

Staccato Loxapine in Agitated Patients With Schizophrenia

Role: lead

NCT00721955Phase 3Completed

Staccato Loxapine in Agitated Patients With Bipolar Disorder

Role: lead

NCT00489476Phase 2Completed

Staccato Loxapine in Migraine (in Clinic)

Role: lead

NCT00477451Phase 2Completed

Staccato Alprazolam in Panic Attack

Role: lead

NCT00825500Phase 2Completed

Staccato Loxapine in Migraine (Out Patient)

Role: lead

NCT00890175Phase 1Completed

Staccato Loxapine Pulmonary Safety in Patients With Asthma

Role: lead